Patient satisfaction is significantly higher with injectable Victoza®

Novo NordiskNew Patient Reported Outcomes (PRO) data presented today at the European Association for the Study of Diabetes (EASD) congress in Stockholm, challenge the widespread perception that patients prefer oral to injected glucose-lowering therapies.(1)

Results from the 26-week, open-label study show that patients taking injectable Victoza® (liraglutide 1.8 mg) reported significantly higher overall treatment satisfaction after 26 weeks than those receiving oral Januvia® (sitagliptin) (scores of 4.35 vs 2.96 respectively, p=0.03).1 Notably, patients rated Victoza® 1.8 mg as convenient as Januvia® and were more likely both to continue treatment themselves, and to recommend Victoza® to another patient.(1)

Additional data from the study demonstrated that both HbA1c reduction(2) and weight loss(3) were significantly greater with Victoza® 1.8 mg than Januvia® when added to a stable dose of metformin. Results presented today show that 50% of patients taking Victoza® 1.8 mg lost >3% of their body weight compared with just 20% of patients taking Januvia®, with the amount of weight loss significantly higher in patients treated with Victoza®.(3)

Study investigator, Professor Melanie Davies from the University Hospitals of Leicester, UK, said: "Some clinicians remain reluctant to use injectable therapies as they perceive them to be more complex and less desirable than oral treatments. However, these findings with Victoza® challenge these perceptions as in our study patients prefer an injected to an oral therapy probably because it offers greater improvement in glycaemic control, and facilitates significant weight loss."

"If as clinicians we want to move to a win-win scenario for our patients, we must look at every factor related to treatment. This of course importantly includes patient reported outcomes and patient satisfaction," said Professor Davies.

Study design

  • This was a 26-week, randomised, open-label, active-comparator, parallelgroup trial in 665 patients with type 2 diabetes. Patients with baseline A1c levels between 7.5 and 10.0% were treated with ≥1,500 mg of metformin and once-daily Victoza® 1.8 mg, Victoza® 1.2 mg or Januvia® 100 mg.

PRO outcomes(1)

  • Improvement in overall treatment satisfaction (TS) measured with the Diabetes Treatment Satisfaction Questionnaire was significantly greater with Victoza® 1.8 mg (4.35) than Januvia® (2.96)
  • Patients reported significantly greater improvement in TS with Victoza® 1.8 mg than Januvia® on three items:
    • In comparison to their 'current treatment' (difference = 0.35; P=0.01)
    • Whether they would 'recommend' Victoza®/Januvia® (difference =0.41; P=0.003)
    • Whether they would 'continue' with Victoza®/Januvia® after study completion (difference = 0.44; P=0.01)
  • Patients perceived themselves to be hyperglycaemic significantly less frequently with Victoza® 1.8 mg than Januvia® (difference = -0.88; P<0.0001).

HbA1c control(2)

  • Victoza® led to significantly greater improvement in glycaemic control than Januvia® (mean HbA1c reduction: 1.50%, 1.24% and 0.90% for Victoza® 1.8 mg, 1.2 mg and Januvia®, respectively; P<0.0001 for both Victoza® doses versus Januvia®. The proportion of patients reaching HbA1c <7%: 54.6%, 43.4% and 22.4%, respectively).

Weight loss(3)

  • More patients lost >3% body weight with Victoza® than Januvia® (51% vs 21%, OR=3.92, p<0.0001)
  • Body weight changes in the >3% body weight change group for Victoza® and Januvia® were -6.3 kg and -5.3 kg respectively.

About Victoza®
Victoza® is the first and only human GLP-1 analogue that is 97% similar to endogenous human GLP-1. Like natural GLP-1, Victoza® (liraglutide) works by stimulating the beta cells to release insulin only when blood sugar levels are high. Due to this glucose-dependent mechanism of action, Victoza® is associated with a low rate of hypoglycaemia. The mechanism of blood sugar lowering also involves a delay in gastric emptying.

Victoza® was approved in June 2009 by the European Commission in all 27 European Union member states. In January 2010 Victoza was approved in the US as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.

As of June 2010, approval has also been granted by the regulatory authorities in Japan, Brazil, Canada and 16 other countries across the world. Victoza® has already been commercially launched in the US, UK, Germany, France, Japan, India, Canada and Denmark as well as 11 other European countries and will be available in other markets throughout 2010. A New Drug Application was also submitted for approval in China in August 2009. A regulatory decision is pending.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

1. Montanya E, Cuddihy R, Pratley R, Hammer M, Bloch-Thomsen A and Davies M. Treatment satisfaction in patients with type2 diabetes is significantly improved with liraglutide, the oncedaily GLP-1 analogue versus sitagliptin, both combined with metformin. 46th European Association for the Study of Diabetes Annual Meeting 20-24 September 2010. Stockholm, Sweden. Poster number 832
2. Davies M, Pratley R, Montanya E, Thomsen AB, Falahati A, Sesti G. Liraglutide reduces A1c to a greater extent than sitagliptin regardless of baseline A1c levels. American Diabetes Association 70th Scientific Sessions, 25 - 29 June 2010. Orlando, Florida. Abstract ID 57-OR
3. Garber A, Thomsen AB, Falahati A, Pratley R. Liraglutide treatment provides greater weight loss with improved glycaemic control than sitagliptin, both combined with metformin. 46th European Association for the Study of Diabetes Annual Meeting 20-24 September 2010. Stockholm, Sweden. Poster number 834

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...